CTI BioPharma Corp. (CTIC)


NasdaqCM - NasdaqCM Real Time Price. Currency in USD
0.38-0.01 (-1.67%)
As of 10:55 AM EDT. Market open.
People also watch:
AGENHEBXOMAKERXARIA
Interactive chart
  • 1d
  • 5d
  • 1m
  • 6m
  • YTD
  • 1y
  • 2y
  • 5y
  • 10y
  • Max
1d
Open0.38
Prev Close0.38
Bid0.38 x 4300
Ask0.38 x 600
Day's Range0.38 - 0.39
52wk Range0.25 - 1.75
1y Target EstN/A
Market Cap106.51M
P/E Ratio (ttm)-1.16
Beta0.43
Volume102,695
Avg Vol (3m)1,047,948
Dividend & YieldN/A (N/A)
Earnings DateN/A
Trade prices are not sourced from all markets
  • PR Newswire5 days ago

    CTI BioPharma Granted 180 Day Extension By NASDAQ To Regain Compliance With Minimum Bid Price Rule

    SEATTLE, Sept. 22, 2016 /PRNewswire/ --  CTI BioPharma Corp. (CTI BioPharma) (NASDAQ and MTA:CTIC) today announced that on September 20, 2016, the NASDAQ Listing Qualifications staff granted the Company an additional 180 calendar day period, or until March 20, 2017, to regain compliance with the Minimum Bid Price Rule. CTI BioPharma Corp. is a biopharmaceutical company focused on the acquisition, development and commercialization of novel targeted therapies covering a spectrum of blood-related cancers that offer a unique benefit to patients and healthcare providers.

  • CTI BioPharma Reports Mixed Pacritinib Study Data, Stock Up
    Zacks28 days ago

    CTI BioPharma Reports Mixed Pacritinib Study Data, Stock Up

    CTI BioPharma (CTIC) announced top-line results from a phase III study (PERSIST-2) on pacritinib for the treatment of myelofibrosis.

  • Benzinga29 days ago

    CTI BioPharma Meets One Of Two Endpoints In Phase 3 Trial

    CTI BioPharma Corp. (NASDAQ: CTIC ) shares are trading higher on Monday after the company announced its preliminary results of PERSIST-2 that met one of the co-primary endpoints in phase three study. Earlier, ...